Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: G-BMT Clear all
Recruiting Phase 2 Interventional

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

NCT01804634
View directory record Official record
Conditions
Refractory and/or Relapsed Metastatic Solid Tumors
Interventions
Cyclophosphamide, Fludarabine, low dose total body irradiation, Melphalan, Tacrolimus
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
1 Year to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
3
States / cities
Baltimore, Maryland • The Bronx, New York • Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 20, 2026, 2:27 PM EDT
Terminated Phase 2 Interventional Results available

Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer

NCT00020722
View directory record Official record
Conditions
Breast Cancer
Interventions
therapeutic autologous lymphocytes, Ifosfamide, carboplatin, and etoposide (ICE) regimen, Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC), Leukapheresis, peripheral blood stem cell transplantation (PBSCT)
Biological · Drug · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 20, 2026, 2:27 PM EDT
Terminated Not applicable Interventional Results available

Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related Donors

NCT02519712
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Induction Chemotherapy, G-PBSC Infusion
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Results available

NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia

NCT02833805
View directory record Official record
Conditions
Severe Aplastic Anemia, Aplastic Anemia, Bone Marrow Failure, Immunosuppression
Interventions
Thymoglobulin, Fludarabine, Cyclophosphamide, Total body irradiation, Tacrolimus, Mycophenolate mofetil
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Results available

Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)

NCT02918292
View directory record Official record
Conditions
Severe Aplastic Anemia
Interventions
Antithymocyte Globulin (ATG), Fludarabine, Cyclophosphamide, Total Body Irradiation (TBI), Haplo HSCT, Tacrolimus, Mycophenolate mofetil (MMF), G-CSF
Drug · Radiation · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
28
States / cities
Duarte, California • Los Angeles, California • Oakland, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 20, 2026, 2:27 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity

NCT06565611
View directory record Official record
Conditions
Obesity
Interventions
bremelanotide, tirzepatide
Drug
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
DeLand, Florida • Oklahoma City, Oklahoma • North Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 3 Interventional

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma

NCT00002548
View directory record Official record
Conditions
Multiple Myeloma
Interventions
recombinant interferon alfa, carmustine, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, melphalan, prednisone, vincristine sulfate, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 70 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
34
States / cities
Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 20, 2026, 2:27 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Pilot Trial of Homebound Stem Cell Transplantation

NCT02671448
View directory record Official record
Conditions
Plasma Cell Dyscrasia
Interventions
Home monitoring teleconsult visits, Patient Reported Outcomes (PRO), Caregiver Reported Outcomes instruments
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Results available

Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

NCT00469014
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
Interventions
Clofarabine, Busulfan, Fludarabine, Stem Cell Infusion, Thymoglobulin (ATG), Filgrastim
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 60 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 20, 2026, 2:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

NCT03500731
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Emphysema or COPD
Interventions
CD3/CD19 negative hematopoietic stem cells, Rituximab, Alemtuzumab, Fludarabine, Thiotepa, G-CSF, Hydroxyurea
Biological · Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 20, 2026, 2:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

NCT03670966
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Cyclophosphamide, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation, Bone Marrow Transplantation, Mycophenolate Mofetil, Recombinant Granulocyte Colony-Stimulating Factor, Fludarabine Phosphate, Tacrolimus, Bone Marrow Aspiration and Biopsy, Biospecimen Collection
Biological · Drug · Radiation + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)

NCT00075829
View directory record Official record
Conditions
Multiple Myeloma
Interventions
One Autologous Transplant, Non-Myeloablative Allogeneic Transplant, Second Autologous Transplant, Thalidomide, Dexamethasone, Observation
Procedure · Drug · Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Up to 70 Years
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 1 Interventional

Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide

NCT01342289
View directory record Official record
Conditions
Hodgkin's Lymphoma, Leukemia, Myelodysplastic Syndrome(MDS), Multiple Myeloma, Non Hodgkin's Lymphoma
Interventions
Cyclophosphamide, Fludarabine, Total body irradiation, Mycophenolate Mofetil, Tacrolimus 60, Tacrolimus 90, Tacrolimus 120, Bone marrow transplant
Drug · Radiation · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 20, 2026, 2:27 PM EDT
Active, not recruiting Phase 2 Interventional

Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia

NCT06752694
View directory record Official record
Conditions
Aplastic Anemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Marrow Transplantation, Computed Tomography, Cyclosporine, Fludarabine, Granulocyte Colony-Stimulating Factor, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Ruxolitinib, Sirolimus, Total-Body Irradiation, Multigated Acquisition Scan, Echocardiography
Procedure · Drug · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Results available

S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

NCT00064337
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Myeloma
Interventions
filgrastim, cyclophosphamide, dexamethasone, melphalan, thalidomide, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
35
States / cities
Little Rock, Arkansas • Sacramento, California • Boise, Idaho + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 20, 2026, 2:27 PM EDT
Terminated Phase 2 Interventional Results available

BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance

NCT02029638
View directory record Official record
Conditions
Kidney Transplantation
Interventions
anti-thymocyte globulin, Fludarabine, Cyclophosphamide, Total Body Irradiation, acetaminophen, diphenhydramine, methylprednisolone, bone marrow transplant, MESNA, mycophenolate mofetil, prednisone, filgrastim
Biological · Drug · Radiation
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)

NCT00075816
View directory record Official record
Conditions
Leukemia, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases
Interventions
Allogeneic bone marrow transplantation, Peripheral blood stem cell transplantation
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 66 Years
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
39
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Results available

Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders

NCT00587054
View directory record Official record
Conditions
Allogeneic Stem Cell Transplant, Leukemia, Non-Hodgkins, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 55 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

NCT00245037
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
Interventions
therapeutic allogeneic lymphocytes, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, Total Body Irradiation (TBI), Granulocyte colony-stimulating factor (G-CSF), Phenytoin, Methotrexate
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 20, 2026, 2:27 PM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 20, 2026, 2:27 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

NCT00792948
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Adult L1 Acute Lymphoblastic Leukemia, Adult L2 Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Leucovorin Calcium, Methotrexate, Methylprednisolone, Peripheral Blood Stem Cell Transplantation, Prednisone, Sirolimus, Tacrolimus, Total-Body Irradiation, Vincristine Sulfate
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 60 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
157
States / cities
Tucson, Arizona • Duarte, California • Palo Alto, California + 114 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Early Phase 1 Interventional

A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma

NCT01171092
View directory record Official record
Conditions
Malignant Lymphoma, Stem Cell Type, Autologous Transplant
Interventions
bortezomib and G-CSF
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Kansas City, Kansas • Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Results available

Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)

NCT00864227
View directory record Official record
Conditions
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
Interventions
Hematopoietic Umbilical Cord Blood Stem Cell Transplantation, GVHD prophylaxis
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
16
States / cities
Duarte, California • Gainesville, Florida • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Oct 20, 2026, 2:27 PM EDT
Recruiting Phase 2 Interventional

Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia

NCT06517641
View directory record Official record
Conditions
Severe Aplastic Anemia
Interventions
Haploidentical donor bone marrow transplant, Unrelated donor bone marrow transplant
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
3 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 20, 2026, 2:27 PM EDT